143 related articles for article (PubMed ID: 35924408)
21. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Marty C; Saint-Martin C; Pecquet C; Grosjean S; Saliba J; Mouton C; Leroy E; Harutyunyan AS; Abgrall JF; Favier R; Toussaint A; Solary E; Kralovics R; Constantinescu SN; Najman A; Vainchenker W; Plo I; Bellanné-Chantelot C
Blood; 2014 Feb; 123(9):1372-83. PubMed ID: 24398328
[TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
Spivak JL; Merchant A; Williams DM; Rogers O; Zhao W; Duffield A; Resar LS; Moliterno AR; Zhao ZJ
PLoS One; 2020; 15(6):e0232801. PubMed ID: 32479500
[TBL] [Abstract][Full Text] [Related]
23. An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.
Favale F; Messaoudi K; Varghese LN; Boukour S; Pecquet C; Gryshkova V; Defour JP; Albu RI; Bluteau O; Ballerini P; Leverger G; Plo I; Debili N; Raslova H; Favier R; Constantinescu SN; Vainchenker W
Blood; 2016 Dec; 128(26):3146-3158. PubMed ID: 28034873
[TBL] [Abstract][Full Text] [Related]
24. A family with hereditary thrombocythaemia and normal genes for thrombopoietin and c-Mpl.
Tecuceanu N; Dardik R; Rabizadeh E; Raanani P; Inbal A
Br J Haematol; 2006 Nov; 135(3):348-51. PubMed ID: 16995886
[TBL] [Abstract][Full Text] [Related]
25. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
Lasho TL; Pardanani A; McClure RF; Mesa RA; Levine RL; Gilliland DG; Tefferi A
Br J Haematol; 2006 Dec; 135(5):683-7. PubMed ID: 17107350
[TBL] [Abstract][Full Text] [Related]
26. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Schnittger S; Bacher U; Haferlach C; Dengler R; Kröber A; Kern W; Haferlach T
Leukemia; 2008 Feb; 22(2):453-5. PubMed ID: 17713548
[No Abstract] [Full Text] [Related]
27. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
28. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellström-Lindberg E; Cazzola M
Blood; 2009 Oct; 114(17):3538-45. PubMed ID: 19692701
[TBL] [Abstract][Full Text] [Related]
29. The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.
Stockklausner C; Klotter AC; Dickemann N; Kuhlee IN; Duffert CM; Kerber C; Gehring NH; Kulozik AE
Blood; 2015 Feb; 125(7):1159-69. PubMed ID: 25538044
[TBL] [Abstract][Full Text] [Related]
30. A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia.
Lambert MP; Jiang J; Batra V; Wu C; Tong W
Am J Hematol; 2012 May; 87(5):532-4. PubMed ID: 22389068
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of the JAK2 V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis.
McCarthy N; McCarron SL; Langabeer SE
Acta Haematol; 2010; 124(3):160-1. PubMed ID: 20938171
[No Abstract] [Full Text] [Related]
32. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.
Giona F; Teofili L; Moleti ML; Martini M; Palumbo G; Amendola A; Mazzucconi MG; Testi AM; Pignoloni P; Orlando SM; Capodimonti S; Nanni M; Leone G; Larocca LM; Foà R
Blood; 2012 Mar; 119(10):2219-27. PubMed ID: 22262773
[TBL] [Abstract][Full Text] [Related]
33. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
34. JAK2, MPL, and CALR mutations in children with essential thrombocythemia.
Sekiya Y; Okuno Y; Muramatsu H; Ismael O; Kawashima N; Narita A; Wang X; Xu Y; Hama A; Fujisaki H; Imamura T; Hasegawa D; Kosaka Y; Sunami S; Ohtsuka Y; Ohga S; Takahashi Y; Kojima S; Shimada A
Int J Hematol; 2016 Aug; 104(2):266-7. PubMed ID: 27209416
[No Abstract] [Full Text] [Related]
35. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
[TBL] [Abstract][Full Text] [Related]
36. Advances in understanding the pathogenesis of familial thrombocythaemia.
Teofili L; Larocca LM
Br J Haematol; 2011 Mar; 152(6):701-12. PubMed ID: 21303356
[TBL] [Abstract][Full Text] [Related]
37. Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm.
Bernal M; Jiménez P; Puerta J; Ruíz-Cabello F; Jurado M
Ann Hematol; 2017 Aug; 96(8):1399-1401. PubMed ID: 28516193
[No Abstract] [Full Text] [Related]
38. Clonal independence of
Thompson ER; Nguyen T; Kankanige Y; Yeh P; Ingbritsen M; McBean M; Semple T; Mir Arnau G; Burbury K; Lee N; Khot A; Westerman D; Blombery P
Haematologica; 2021 Jan; 106(1):313-315. PubMed ID: 32817290
[No Abstract] [Full Text] [Related]
39. Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C; Duffert CM; Cario H; Knöfler R; Streif W; Kulozik AE;
Ann Hematol; 2021 Jul; 100(7):1647-1665. PubMed ID: 33712866
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.
Boyd EM; Bench AJ; Goday-Fernández A; Anand S; Vaghela KJ; Beer P; Scott MA; Bareford D; Green AR; Huntly B; Erber WN
Br J Haematol; 2010 Apr; 149(2):250-7. PubMed ID: 20151976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
